This page shows the details of why an item matched the keywords from your search.
Item Type | Name |
Academic Article
|
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
|
Academic Article
|
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
|
Academic Article
|
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
|
Academic Article
|
Current strategies for treatment of relapsed/refractory multiple myeloma.
|
Academic Article
|
Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
|
Academic Article
|
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
|
Academic Article
|
Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.
|
Academic Article
|
Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.
|
Academic Article
|
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.
|
Academic Article
|
A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia.
|
Academic Article
|
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.
|
Academic Article
|
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
|
Academic Article
|
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
|
Academic Article
|
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.
|
Academic Article
|
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
|
Concept
|
Proteasome Inhibitors
|
- Proteasome Endopeptidase Complex